See more : China Demeter Financial Investments Limited (8120.HK) Income Statement Analysis – Financial Results
Complete financial analysis of Codexis, Inc. (CDXS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Codexis, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Allianz Ayudhya Capital Public Company Limited (AYUD.BK) Income Statement Analysis – Financial Results
- Max Sound Corporation (MAXD) Income Statement Analysis – Financial Results
- China Silver Technology Holdings Limited (0515.HK) Income Statement Analysis – Financial Results
- The Stanley Gibbons Group plc (SGI.L) Income Statement Analysis – Financial Results
- First Eagle Alternative Capital BDC, Inc. (FCRX) Income Statement Analysis – Financial Results
Codexis, Inc. (CDXS)
About Codexis, Inc.
Codexis, Inc. discovers, develops, and sells enzymes and other proteins. It offers biocatalyst products and services; intermediate chemicals products that are used for further chemical processing; and Codex biocatalyst panels and kits that enable customers to perform chemistry screening. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver protein engineering technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes. The company's platform is also used to discover novel biotherapeutic drug candidates for targeted human diseases, as well as for molecular biology and in vitro diagnostic enzymes. It sells its products to pharmaceutical manufacturers through its direct sales and business development force in the United States and Europe. The company was incorporated in 2002 and is headquartered in Redwood City, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 70.14M | 138.59M | 104.75M | 69.06M | 68.46M | 60.59M | 50.02M | 48.84M | 41.80M | 35.31M | 31.92M | 88.30M | 123.87M | 107.10M | 82.91M | 50.48M | 25.33M | 12.13M |
| Cost of Revenue | 12.81M | 38.03M | 22.21M | 13.74M | 15.63M | 12.62M | 14.33M | 9.75M | 6.59M | 9.73M | 14.55M | 30.65M | 41.78M | 27.98M | 16.68M | 13.19M | 8.32M | 1.81M |
| Gross Profit | 57.33M | 100.56M | 82.55M | 55.31M | 52.83M | 47.97M | 35.70M | 39.08M | 35.22M | 25.58M | 17.37M | 57.65M | 82.08M | 79.12M | 66.23M | 37.29M | 17.01M | 10.32M |
| Gross Profit Ratio | 81.74% | 72.56% | 78.80% | 80.10% | 77.17% | 79.17% | 71.36% | 80.03% | 84.25% | 72.45% | 54.41% | 65.29% | 66.27% | 73.87% | 79.88% | 73.87% | 67.16% | 85.11% |
| Research & Development | 58.89M | 80.10M | 55.92M | 44.19M | 33.87M | 29.98M | 29.66M | 22.23M | 20.67M | 22.76M | 31.61M | 56.79M | 61.05M | 52.41M | 54.73M | 45.55M | 35.64M | 17.26M |
| General & Administrative | 52.95M | 51.87M | 49.02M | 34.75M | 31.00M | 28.79M | 28.31M | 24.92M | 22.02M | 21.64M | 26.41M | 30.98M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 300.00K | 300.00K | 300.00K | 300.00K | 500.00K | 500.00K | 700.00K | 500.00K | 300.00K | 300.00K | 500.00K | 400.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 53.25M | 52.17M | 49.32M | 35.05M | 31.50M | 29.29M | 29.01M | 25.42M | 22.32M | 21.94M | 26.91M | 31.38M | 36.94M | 33.84M | 29.87M | 35.71M | 19.71M | 11.88M |
| Other Expenses | 13.27M | 124.00K | 1.15M | -156.00K | -656.00K | -291.00K | -92.00K | -94.00K | -168.00K | -234.00K | 24.74M | -326.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 125.40M | 132.27M | 105.24M | 79.23M | 65.38M | 59.27M | 58.67M | 47.65M | 42.99M | 44.69M | 58.51M | 88.16M | 97.99M | 86.25M | 84.60M | 81.26M | 55.36M | 29.14M |
| Cost & Expenses | 138.21M | 170.30M | 127.45M | 92.98M | 81.01M | 71.89M | 72.99M | 57.40M | 49.57M | 54.42M | 73.07M | 118.81M | 139.77M | 114.23M | 101.27M | 94.45M | 63.68M | 30.94M |
| Interest Income | 4.17M | 1.44M | 459.00K | 405.00K | 1.29M | 671.00K | 147.00K | 60.00K | 19.00K | 18.00K | 60.00K | 252.00K | 273.00K | 166.00K | 180.00K | 1.54M | 1.49M | 742.00K |
| Interest Expense | 0.00 | 1.44M | 0.00 | 0.00 | 0.00 | 671.00K | 147.00K | 60.00K | 19.00K | 18.00K | 304.00K | 274.00K | 675.00K | 1.20M | 2.04M | 2.37M | 2.53M | 724.00K |
| Depreciation & Amortization | 9.92M | 10.25M | 5.95M | 4.55M | 4.77M | 1.15M | 1.04M | 4.55M | 5.41M | 6.69M | 10.32M | 12.42M | 11.47M | 8.31M | 6.13M | 4.56M | 2.88M | 2.39M |
| EBITDA | -49.28M | -23.07M | -16.75M | -19.37M | -7.99M | -10.15M | -21.93M | -4.02M | -2.36M | -12.64M | -31.07M | -18.17M | -4.84M | 681.00K | -12.06M | -37.87M | -35.67M | -15.69M |
| EBITDA Ratio | -70.26% | -20.60% | -21.67% | -34.64% | -18.33% | -18.64% | -45.92% | -17.54% | -18.59% | -54.13% | -128.71% | -34.56% | -3.36% | 1.26% | -14.54% | -75.03% | -134.09% | -129.36% |
| Operating Income | -68.07M | -31.71M | -22.70M | -23.92M | -12.55M | -11.30M | -22.97M | -8.56M | -7.77M | -19.11M | -41.15M | -30.51M | -15.91M | -7.12M | -18.37M | -43.97M | -38.34M | -18.82M |
| Operating Income Ratio | -97.04% | -22.88% | -21.67% | -34.64% | -18.33% | -18.64% | -45.92% | -17.54% | -18.59% | -54.13% | -128.90% | -34.56% | -12.84% | -6.65% | -22.15% | -87.11% | -151.36% | -155.16% |
| Total Other Income/Expenses | -8.10M | 1.57M | 1.61M | 249.00K | 631.00K | 380.00K | 55.00K | -34.00K | -149.00K | -216.00K | -244.00K | -74.00K | -402.00K | -1.03M | -1.86M | -827.00K | -1.04M | 18.00K |
| Income Before Tax | -76.17M | -33.32M | -21.09M | -23.67M | -11.92M | -10.92M | -22.92M | -8.60M | -7.92M | -19.33M | -41.39M | -30.59M | -16.31M | -8.16M | -20.22M | -44.80M | -39.39M | -18.80M |
| Income Before Tax Ratio | -108.59% | -24.04% | -20.13% | -34.28% | -17.41% | -18.01% | -45.81% | -17.61% | -18.94% | -54.74% | -129.66% | -34.64% | -13.17% | -7.62% | -24.39% | -88.75% | -155.47% | -155.01% |
| Income Tax Expense | 69.00K | 276.00K | 189.00K | 339.00K | 17.00K | -37.00K | 81.00K | -40.00K | -338.00K | -256.00K | -87.00K | 270.00K | 241.00K | 384.00K | 66.00K | 327.00K | -408.00K | -127.00K |
| Net Income | -76.24M | -33.59M | -21.28M | -24.01M | -11.94M | -10.88M | -23.00M | -8.56M | -7.58M | -19.07M | -41.30M | -30.86M | -16.55M | -8.54M | -20.29M | -45.13M | -38.98M | -18.67M |
| Net Income Ratio | -108.69% | -24.24% | -20.31% | -34.77% | -17.43% | -17.95% | -45.97% | -17.52% | -18.13% | -54.01% | -129.39% | -34.95% | -13.36% | -7.97% | -24.47% | -89.40% | -153.86% | -153.96% |
| EPS | -1.12 | -0.51 | -0.33 | -0.40 | -0.21 | -0.21 | -0.50 | -0.21 | -0.19 | -0.50 | -1.08 | -0.84 | -0.46 | -0.35 | -7.74 | -16.63 | -14.36 | -6.88 |
| EPS Diluted | -1.12 | -0.51 | -0.33 | -0.40 | -0.21 | -0.21 | -0.50 | -0.21 | -0.19 | -0.50 | -1.08 | -0.84 | -0.46 | -0.35 | -7.74 | -16.63 | -14.36 | -6.88 |
| Weighted Avg Shares Out | 68.13M | 65.34M | 64.57M | 59.36M | 56.53M | 52.21M | 46.23M | 40.63M | 39.44M | 38.21M | 38.23M | 36.77M | 35.67M | 24.59M | 2.62M | 2.71M | 2.71M | 2.71M |
| Weighted Avg Shares Out (Dil) | 68.13M | 65.34M | 64.57M | 59.36M | 56.53M | 52.21M | 46.23M | 40.63M | 39.44M | 38.21M | 38.23M | 36.77M | 35.67M | 24.59M | 2.62M | 2.71M | 2.71M | 2.71M |
Up Over 500% in the Last 5 Years, Can This Biotech Continue Its Hot Streak?
Codexis is leveraging its core technology to create more effective life science tools.
Codexis, Almelo and RC2 Announce a Tri-Party Collaboration for the Enzymatic Production of Low Cost Sitagliptin API for the Generic Market, Including a License to Codexis Enzyme Technology in India
REDWOOD CITY, Calif., Oct. 18, 2021 (GLOBE NEWSWIRE) -- Codexis, Inc. (Nasdaq: CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, announced a tri-party collaboration agreement with Almelo Private, Ltd., an Indian producer of active pharmaceutical ingredients...
Codexis (CDXS) Surges 12.4%: Is This an Indication of Further Gains?
Codexis (CDXS) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Codexis, Merck Extend Supply Pact For Enzyme Used To Manufacture Sitagliptin
Codexis Inc (NASDAQ: CDXS) has amended and extended its agreement with Merck & Co Inc (NYSE: MRK) to license and supply a proprietary enzyme used to manufacture sitagliptin. Sitagliptin is an active pharmaceutical ingredient (API) in Merck's two anti-diabetic medications, Januvia and Janumet.
Codexis and Merck Amend and Extend Supply Agreement for Enzyme Used in Manufacture of Sitagliptin
REDWOOD CITY, Calif., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Codexis, Inc. (Nasdaq: CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, announced the amendment and extension of its agreement with Merck, known as MSD outside the United...
Codexis to Participate in Upcoming Virtual Healthcare Conferences
REDWOOD CITY, Calif., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Codexis, inc. (Nasdaq:CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, today announced that management will participate in two upcoming virtual investment conferences.
After Golden Cross, Codexis (CDXS)'s Technical Outlook is Bright
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
Codexis, Inc. (CDXS) CEO John Nicols on Q2 2021 Results - Earnings Call Transcript
Codexis, Inc. (CDXS) CEO John Nicols on Q2 2021 Results - Earnings Call Transcript
Codexis (CDXS) Reports Q2 Loss, Tops Revenue Estimates
Codexis (CDXS) delivered earnings and revenue surprises of 58.82% and 41.06%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Codexis and Kalsec Announce Expanded Collaboration for Supply of Novel Enzyme to Sustainably Produce Natural Clean-Label Beverage Ingredient
REDWOOD CITY, Calif. and KALAMAZOO, Mich., Aug. 02, 2021 (GLOBE NEWSWIRE) -- Codexis, Inc. (Nasdaq: CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, and Kalsec, Inc., a leading global producer of natural spice and herb extracts,...
Source: https://incomestatements.info
Category: Stock Reports